The rationale for our trial relies on the fact that TNAP activity is higher and PPi is lower in PXE patients compared with non-PXE subjects [3,4], and that TNAP activity could be partially inhibited by lansoprazole [14]. This evidence concerns the gene ALPL and Pseudoxanthoma elasticum.